Andrea Ventura

Has grant

Member

Memorial Sloan Kettering Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Investigating the roles of oncogenic extrachromosomal circular DNAs in cancer

Open Date: 2023-08-01

Close Date: 2028-07-31

Grant: Close

Investigating the role of ecDNAs in cancer initiation and progression

Open Date: 2023-07-01

Close Date: 2025-07-01

Grant: Close

Investigating microRNA Function in Homeostasis, Regeneration and Cancer

Open Date: 2020-09-01

Close Date: 2025-05-31

Grant: Close

Modeling BRAF-fusion driven pediatric brain tumors in the mouse

Open Date: 2019-06-01

Close Date: 2024-05-31

Grant: Close

Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibition

Open Date: 2018-05-18

Close Date: 2023-04-30

Articles (16)

Year:

2026

High-level copy-number (CN) amplification (HLAMP) is a major mechanism of oncogene activation in human cancer. Despite progress in therapeutically targeting HLAMPs, the processes underlying HLAMP evolution are incompletely understood, leaving critical knowledge gaps in their etiology and mechanisms of therapeutic response. To address this, we analyzed using novel computational approaches, the evolutionary trajectories of HLAMP in single-cell whole-genome sequencing of 86,239 cancer cells from 94 patients and 8 experimental systems. We found that two common etiologies of oncogene amplification - intrachromosomal amplification (ICamp) and extrachromosomal circular DNA (ecDNA) - lead to distinct CN distributions across cells in amplitude, variance and clone specificity. Notably, ICamp events exhibited widespread subclonal specificity, indicating their dynamic evolution through numeric or structural modulation associated with clonal expansions. In contrast, ecDNAs exhibited higher cell-to-cell CN variation linked to structural rearrangements, whereby complex ecDNA architectures were resolved at single-nucleotide resolution in individual cell genomes. Through joint analysis of ecDNA structure and their cellular abundance, we observed both divergent and convergent modes of ecDNA evolution shaped by DNA damage, selection, and chromosomal re-integration. Finally, modeling single-cell distributions of ecDNAs substantially improved bulk genome-graph based predictions, revealing that ecDNA prevalence is tissue-type specific, rather than broadly shared across cancer types, with implications for ecDNA-directed therapy.

Year:

2026

There is growing interest in understanding the mechanisms underlying differences in cancer incidence among species (comparative oncology). The naked mole rat (NMR) is often referenced as “cancer resistant” and prior studies focused on identifying mechanisms explaining this. However, efforts to assess this in vivo have been limited. In this study, we provide evidence that the NMR presents as a novel autochthonous model of lung tumor initiation, driven by an introduction of the oncogenic Eml4-Alk fusion gene using CRISPR-mediated genome editing. Although in mice, the inversion alone is sufficient to drive tumorigenesis, the inversion alone was insufficient to drive tumorigenesis in the NMR lung, and tumor development required additional losses of the tumor suppressors p53 and pRb. Our findings suggest that the proposed “resistance” of the NMR to the development of cancer may reflect that the genetic events leading to tumor initiation are likely to be comparable with those present in human cells. Significance: To identify evolutionary divergent mechanisms of cancer resistance, we assessed tumorigenesis in vivo using the NMR, a species considered to exhibit cancer resistance. Our findings suggest that the proposed “resistance” of NMRs to the development of cancer may reflect tumor initiation mechanisms comparable with the mechanisms present in humans. See related commentary by Boddy and Abegglen, p. 7

Year:

2026

Year:

2025

Excised signal circles (ESC) are circular DNA molecules generated during T‐ and B‐cell maturation. Previously considered biologically inert, recent work by Gao et al . now show that ESCs can replicate and accumulate in healthy lymphocytes. Moreover, the authors link higher levels of ESCs to an increased risk of relapse in B‐cell leukemia patients and propose that this phenomenon is due to the unique ability of ESCs to induce genome instability.

Year:

2025

We present GuideScan2 for memory-efficient, parallelizable construction of high-specificity CRISPR guide RNA (gRNA) databases and user-friendly design and analysis of individual gRNAs and gRNA libraries for targeting coding and non-coding regions in custom genomes. GuideScan2 analysis identifies widespread confounding effects of low-specificity gRNAs in published CRISPR screens and enables construction of a gRNA library that reduces off-target effects in a gene essentiality screen. GuideScan2 also enables the design and experimental validation of allele-specific gRNAs in a hybrid mouse genome. GuideScan2 will facilitate CRISPR experiments across a wide range of applications.

Year:

2025

Workflow of the study analysis. A, A total of 94 IDH wt GBMs were analyzed (35 from the PCAWG cohort and 59 from the GB-UK cohort). B, The core region of all patient tumors was analyzed using WGS, and GB-UK patient tumors were further subjected to multiregion DNA FISH and nascent RNAscope analysis to characterize spatial patterns of oncogenic ecDNAs. C, The ecDNA genetic landscape and fine structure were analyzed using WGS information, and mathematical modeling of single-cell copy number was employed to reconstruct evolutionary histories in GB-UK patient tumors. ( B, created using BioRender assets. https://BioRender.com/kgae4q5 ; https://BioRender.com/7f2pume )

Year:

2025

Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA. We observe oncogene-specific patterns of ecDNA spatial heterogeneity, emerging from random ecDNA segregation and differing fitness advantages. Unlike PDGFRA -ecDNAs, EGFR -ecDNAs often accumulate prior to clonal expansions, conferring strong fitness advantages and reaching high abundances. In corroboration, we observe pretumor ecDNA accumulation in vivo in genetically engineered mouse neural stem cells. Variant and wild-type EGFR -ecDNAs often coexist in GBM. Those variant EGFR -ecDNAs, most commonly EGFRvIII -ecDNA, always derive from preexisting wild-type EGFR -ecDNAs, occur early, and reach high abundance. Our results suggest that the ecDNA oncogenic makeup determines unique evolutionary trajectories. New concepts such as ecDNA clonality and heteroplasmy require a refined evolutionary interpretation of genomic data in a large subset of GBMs. Significance: We study spatial patterns of ecDNA-amplified oncogenes and their evolutionary properties in human GBM, revealing an ecDNA landscape and ecDNA oncogene–specific evolutionary histories. ecDNA accumulation can precede clonal expansion, facilitating the emergence of EGFR oncogenic variants, reframing our interpretation of genomic data in a large subset of GBMs. See related commentary by Korsah et al., p. 1979

Year:

2025

Simulating multi-ecDNA dynamics in vivo. A, DNA FISH and nascent RNAscope images from the tumor of patient A5, showing the coexistence of both EGFR -ecDNA and PDGFRA -ecDNA. B, Circular structures of three distinct oncogenic ecDNAs detected in the tumor of patient A5. C, GBMs in the GB-UK and PCAWG cohorts containing more than one oncogenic species and their respective copy numbers. D, In a multiple-ecDNA application of SPECIES, the clone-initiating cell begins with k 1 and k 2 copies of ecDNA 1 and ecDNA 2, respectively. E, Representation of the impacts of ecDNA cosegregation and coselection on the number of inherited ecDNA copies during cell division. Cosegregation drives correlated inheritance of both ecDNA types, whereas coselection favors tumor cells carrying at least one copy of each type. F, Application of SPECIES to simulate two separate ecDNA species. Simulated tumors were initialized with a single cell, carrying k 1 and k 2 copies of each ecDNA species. Representative model images show examples of low and high cosegregation and coselection. G and H, Parameter inference summary for the tumor of patient A5, for which we measured both the EGFR -ecDNA and PDGFRA -ecDNA copy-number distributions using DNA FISH, using multiple-ecDNA SPECIES. Parameters s p and s m represent selection coefficients for tumor cells with 1 (pure) or 2 (mixed) ecDNA species, respectively. I, Comparison of inferred k and k 1 values for all patient tumors confirmed by WGS to harbor two or more ecDNA species. J, The presence of ecDNA amplifications may be used to aid stratification, given that oncogenes on ecDNA have an inherent resistance mechanism through the ability of ecDNA to dynamically adjust copy number in response to targeted agents. Earlier monitoring and intervention are recommended for those patient tumors with ecDNA that will receive targeted therapies.

Year:

2025

Selection dynamics of EGFR SVs on ecDNA. A, A subclonal EGFRvIII variant on ecDNA in the tumor of patient A23. B, Variant heteroplasmy in the core region of all samples across the GB-UK and PCAWG cohorts, which contained EGFR variant–bearing ecDNA. C, Effects of (i) pre- and (ii) postclonal expansion mutation of EGFR -ecDNA on its resulting spatial pattern in the expanded tumor. D, SPECIES was applied to simulate the emergence of an advantageous EGFRvIII mutation on ecDNA, either prior to or after the onset of clonal expansion of the tumor. The example shown is for a pre-expansion mutation, with parameters ( k w t = 20 , k v a r = 1 , V v a r = 0 ). The SD of ecDNA heteroplasmy is shown by the shaded region in the lower plot. E, Model predictions for resulting variant heteroplasmy in a tumor for a range of wild type- and variant-bearing ecDNA copy numbers in the clone-initiating tumor cell (for pre-expansion EGFR mutation) and mutation times (for post-expansion EGFR mutation). The red-shaded region denotes parameter combinations inconsistent with observed patient core heteroplasmy values. Mean ± variance is derived from 1,000 simulated tumors. F, SPECIES model predictions for the probability of observing EGFRvIII ecDNA across tumor core and margin, for a pair of core and random margin regions. Mean values are derived from 1,000 simulated tumors. G, (Top) IHC slide for the tumor of patient A20, showing the presence of EGFRvIII in the tumor core and infiltrating margin (blue = hematoxylin; brown = EGFRvIII ). (Bottom) Summary of EGFRvIII in core and margins of GB-UK cohort samples, determined by IHC. H, Variant allele frequencies of point mutations within EGFR in PCAWG samples harboring EGFR -ecDNA. Red lines represent the frequency expected for a mutation carried by all ecDNAs within a sample. I, Distributions of EGFR wt-ecDNA abundance in the cell that acquires the first mutation, for a range of ecDNA mutation rates. Patient tumor values are derived from their respective inferred k values, assuming that the arrival of a mutation on ecDNA initiates clonal expansion, implying that the number of EGFR wt-ecDNA in the mutating cell is thus equal to k − 1 (with the remaining one ecDNA carrying the mutated allele). J, Timeline of EGFR -ecDNA tumorigenesis. ( i ) Initial EGFR wt-ecDNA is generated and accumulates in precancerous cells, conferring a moderately positive selective advantage. In time, the EGFRvIII mutation occurs on one of the accumulated EGFR wt-ecDNAs, conferring a strong positive advantage. ( ii ) Reconstructed ecDNA structures from the tumor of GB-UK patient A5 confirm that EGFR wt and EGFRvIII ecDNAs share common breakpoints, indicating that EGFRvIII arose from the mutation of an existing EGFR wt-ecDNA. (iii) EGFRvIII -ecDNA further promotes clonal expansion, driving tumor growth.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Collaborators (26)

Walid Khaled

University lecturer

University of Cambridge

UNITED KINGDOM
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Viviane Tabar

Chair Neurosurgery/Member

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Thomas Park

Professor

University of Chicago

UNITED STATES
View details

Vineet Bafna

Professor

University of California, San Diego

UNITED STATES
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Eric Sun

Tri-Institutional MD-PhD Program

UNITED STATES
View details

Benjamin Werner

Reader in Somatic Evolution

Barts Cancer Institute

UNITED KINGDOM
View details

Mariam Jamal-Hanjani

Group Leader and Thoracic Oncologist

University College London

UNITED KINGDOM
View details

Charles Rudin

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Ewan Smith

Head of Department

University of Cambridge

UNITED KINGDOM
View details

Christine Crish

Associate Professor (tenured)

Northeast Ohio Medical University

UNITED STATES
View details

Sohrab Shah

Professor

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Elsa Flores

Associate Center Director, Basic Science

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Samuel Aparicio

Head

-

CANADA
View details

Thomas Santarius

University of Cambridge

UNITED KINGDOM
View details

Susumu Kobayashi

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Matthew Jones

Assistant Professor

Massachusetts Institute of Technology

UNITED STATES
View details

Howard Y. Chang

Stanford University School of Medicine

UNITED STATES
View details

Clare Weeden

The Francis Crick Institute

UNITED KINGDOM
View details

Delphine Boche

Professor of Neuroimmunopathology

University of Southampton

UNITED KINGDOM
View details

Weini Huang

Senior Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Andrew McPherson

Assistant Attending

Sloan Kettering Institute

UNITED STATES
View details

Kenneth Tsai

Vice Chair of Research, Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paul S. Mischel

Stanford University School of Medicine

UNITED STATES
View details

Mary Green

Deputy Head of Experimental Histopathology

The Francis Crick Institute

UNITED KINGDOM
View details